AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02015728
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.
Trial: NCT02015728
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib is a broad spectrum SRC inhibitor.
Trial: NCT02352701
Drug: Chongkundang Amoxicillin Cap. 500mg
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1000mg, BID dosage form : capsule
Trial: NCT03604224
Drug: Canagliflozin 300 mg
RxNorm normalized name: canagliflozin 300 MG
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.
Trial: NCT01037218
Drug: Udenafil
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets via oral administration before an attempt at sexual intercourse.
Trial: NCT00150735
Drug: LEVETIRACETAM
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03024502
Drug: Clotrimazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration intravaginal of clotrimazol, 1x/day, 7 days
Trial: NCT00897715
Drug: Rilonacept
RxNorm normalized name: Rilonacept
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 160 mg of rilonacept administered subcutaneously once a week for 12 weeks
Trial: NCT01268553
Drug: Treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transition to inhaled treprostinil
Trial: NCT02591277
Drug: Harvoni
RxNorm normalized name: Harvoni
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Harvoni (90/400 mg) FDC tablet administered orally once daily
Trial: NCT01404767
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline treatment consists of a bolus of 500ug/kg/min followed by an infusion of 50ug/kg/min for 4 minutes and titrating in increment of 50ug/kg/min up to a maximum of 300ug/kg/min to maintain a HR within 10% of the target HR (≤ 70 bpm), which is 70± 7 bpm.
Trial: NCT01404767
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The night and morning before surgery, the patients in the metoprolol arm will receive their standard dose of beta blocker metoprolol.These patients will receive their daily beta blockers orally or via nasogastric tube postoperatively if they are NPO (Group A).
Trial: NCT00279435
Drug: visilizumab
RxNorm normalized name: Visilizumab
DrugBank: Visilizumab (DB12053)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00139451
Drug: GH
RxNorm normalized name: hGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone will be 0.3mg/kg/week, given SC once daily.
Trial: NCT01571323
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it)
Trial: NCT01571323
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate
Trial: NCT01571323
Drug: Oxytocin and Misoprostol
RxNorm normalized name: naproxen and misoprostol
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate .
Trial: NCT00240721
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02954484
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: see arm/group description. Lyrica manufacture site: Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany.
Trial: NCT02954484
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol 1g per oral 6hourly on postoperative days 1,2,3. Manufacture site: SM Pharmaceuticals, Malaysia
Trial: NCT02954484
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient-controlled analgesia intravenous morphine sulphate on postoperative days 1,2,3.~Manufacture site: Hameln Pharma Plus GMBH, Hameln, Germany
Trial: NCT02954484
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Femoral block with ropivacaine 0.5% 30mls. Ropivacaine manufacture site: AstraZeneva AB, Sweden
Trial: NCT04162743
Drug: Trazodone
RxNorm normalized name: Trazodone
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: take trazodone 100mg before polysomnography
Trial: NCT00455403
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24
Trial: NCT02391688
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02391688
Drug: Fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03238651
Drug: TAK-659
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-659 Tablets.
Trial: NCT00923741
Drug: Talactoferrin
RxNorm normalized name: Talactoferrin alfa
DrugBank: Talactoferrin alfa (DB05426)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00218387
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg Modafinil
Trial: NCT00218387
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg Modafinil
Trial: NCT03525561
Drug: Acetazolamide Pill
RxNorm normalized name: acetazolamide Pill
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take acetazolamide pill (Diamox), 500 mg/ day, and assess effect on exercise performance during 30-hour exposure to 3,500 m simulated altitude.
Trial: NCT00666328
Drug: clevidipine
RxNorm normalized name: Clevidipine
DrugBank: Clevidipine (DB04920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.~Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours.
Trial: NCT03830489
Drug: polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet
Trial: NCT01901640
Drug: DA-8159 (Udenafil)
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01963546
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After selecting the appropriate anesthesia method, assess the effect of dexmedetomidine on controlling stress response from diabetics undergoing laparoscopic gastric-bypass surgical.The stress indicators are the same as described above.
Trial: NCT02288325
Drug: Levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.
Trial: NCT00520377
Drug: MD05
RxNorm normalized name: MD05
DrugBank: MD05 (DB06375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant human GDF-5 coated onto beta-tricalcium phosphate
Trial: NCT02140151
Drug: Ranibizumab 0.5mg
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00573690
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00573690
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00573690
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00573690
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00573690
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01593670
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered intravenous (IV), 10 mg/m\^2/day over 1 hour on days 1-5.
Trial: NCT01593670
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg by mouth (PO) twice a day on days 6-15
Trial: NCT01186068
Drug: V-101
RxNorm normalized name: AV-101
DrugBank: AV-101 (DB12878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream QD
Trial: NCT01836471
Drug: Fluticasone 250 mcg
RxNorm normalized name: fluticasone 250 mcg/inh inhalation powder
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone was supplied in inhalers with dose strength of 250 mcg. Patients took 250 mcg bid (morning and evening approximately 12 hours between doses) for a total dose of 500 mcg daily for the approximate period of the study (12 weeks).
Trial: NCT01836471
Drug: Fluticasone 100 mcg
RxNorm normalized name: fluticasone 100 mcg/inh inhalation powder
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).
Trial: NCT01996930
Drug: Haelan tape (steroid impregnated tape)
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medicated plaster applied daily. Max daily dose = 0.1mg (25cm squared per day)Maximum duration of treatment = 28 days
Trial: NCT01996930
Drug: Silver Nitrate
RxNorm normalized name: Silver Nitrate
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cautery with silver nitrate cutaneous stick undertaken twice weekly for a maximum duration of treatment = 28 days
Trial: NCT02877225
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib (test treatment) 140 milligram (mg), tablet.
Trial: NCT02877225
Drug: IMBRUVICA
RxNorm normalized name: Imbruvica
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IMBRUVICA (reference treatment), 140-mg capsule
Trial: NCT03881293
Drug: lidocaine 2% gel
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transurethral instillation of 5 ml lidocaine 2% gel
Trial: NCT03881293
Drug: water soluble lubricant
RxNorm normalized name: WATER SOLUBLE BASE
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral instillation of 5 ml water soluble lubricant
Trial: NCT00592306
Drug: thymoglobulin (intraoperative)
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses.
Trial: NCT00592306
Drug: thymoglobulin (postoperative)
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin.
Trial: NCT01868906
Drug: 18F-FMISO
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.
Trial: NCT01868906
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard treatment with concurrent and adjuvant Temozolomide.
Trial: NCT03732664
Drug: Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One to four doses of anti-PD-1 or anti-PD-L1 antibody will be administered to enrolled patients on Day -56, Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days.
Trial: NCT00826969
Drug: Ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 320µg Ciclesonide versus Placebo
Trial: NCT01060072
Drug: Loteprednol etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical administration of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye four times a day (QID), postoperative day 1-14.
Trial: NCT01060072
Drug: Vehicle of Loteprednol Etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical administration of vehicle of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye QID, postoperative day 1-14.
Trial: NCT00837148
Drug: Sorafenib and Dacarbazine
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment will be administered on an outpatient basis. Sorafenib is supplied as 200-mg tablets. The starting dose of sorafenib will be 400 mg PO twice daily (every 12 hours) continuously. There is no planned treatment interruption between cycles.~All patients will receive dacarbazine as an open-label dose of 850 mg/m2 by IV infusion over 60 minutes, starting on Week 1 and repeated every 3 weeks until disease progression or intolerance.
Trial: NCT00235755
Drug: Retigabine
RxNorm normalized name: retigabine
DrugBank: Ezogabine (DB04953)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
Trial: NCT00235755
Drug: Retigabine
RxNorm normalized name: retigabine
DrugBank: Ezogabine (DB04953)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
Trial: NCT01014546
Drug: Arsenic Trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02949973
Drug: voclosporin
RxNorm normalized name: Voclosporin
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01125917
Drug: Buprenorphine transdermal patch
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
Trial: NCT01125917
Drug: Buprenorphine transdermal patch
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
Trial: NCT01125917
Drug: Buprenorphine transdermal patch
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
Trial: NCT01522456
Drug: Epiduo Gel
RxNorm normalized name: Epiduo
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
Trial: NCT00571324
Drug: Exendin-(9-39)
RxNorm normalized name: Exendin 4
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.
Trial: NCT04386850
Drug: Oral 25-Hydroxyvitamin D3
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the case group will receive 25 mcg of 25(OH)D3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months.
Trial: NCT04876638
Drug: Minocyclin
RxNorm normalized name: Minocyclin
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/kg minocycline up to 700mg for 4 days following aneurysmal subarachnoid hemorrhage
Trial: NCT04272788
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The CD patients at initial active stage without treatment of glucocorticoids, immunosuppressants and biological agents are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
Trial: NCT05872789
Drug: Diazepam 1% oral gel
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam 1% used with topic oral gel on tongue and palate twice daily.
Trial: NCT01785082
Drug: 13-C-Methacetin
RxNorm normalized name: Urea C 13
DrugBank: Methacetin methoxy-C-13 (DB15885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection of 0.4% 13-C-Methacetin solution, once before partial liver resection, once after partial liver resection
Trial: NCT01838369
Drug: BI-505
RxNorm normalized name: Anti-icam-1 monoclonal antibody bi-505
DrugBank: Bersanlimab (DB17377)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03466450
Drug: PF-04449913
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered:~During concurrent phase concomitantly with radiation and Extended to the resting period (glasdegib will not be stopped in the 4 weeks of radiotherapy resting period).~During adjuvant therapy with Temozolomide Oral Capsule. Additional treatment with glasdegib beyond 6 sequential TMZ cycles will continue until progression, unacceptable toxicity, non-compliance, consent withdrawal and/or 2 years of glasdegib administration.
Trial: NCT03466450
Drug: Temozolomide Oral Capsule
RxNorm normalized name: temozolomide Oral Capsule
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During RT, patients will receive Temozolamide (TMZ). All patients will be given TMZ at 75 mg/m2~/d concurrently with RT for a maximum of 42 days. At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles.
Trial: NCT02537561
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02537561
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02537561
Drug: Talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00477737
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00477737
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no